{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T11:01:02Z","timestamp":1742382062256,"version":"3.37.3"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1124\/jpet.110.172288","type":"journal-article","created":{"date-parts":[[2010,11,4]],"date-time":"2010-11-04T01:11:39Z","timestamp":1288833099000},"page":"365-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder"],"prefix":"10.1016","volume":"336","author":[{"given":"Shizuo","family":"Yamada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanao","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Ogoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Fukata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miho","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.110.172288_bib1","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1464-410X.2007.07205.x","article-title":"Muscarinic receptor antagonists for overactive bladder","volume":"100","author":"Abrams","year":"2007","journal-title":"BJU international"},{"key":"10.1124\/jpet.110.172288_bib2","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1136\/bmj.38740.439664.DE","article-title":"Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study","volume":"332","author":"Ancelin","year":"2006","journal-title":"BMJ"},{"key":"10.1124\/jpet.110.172288_bib3","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0031-6997(25)00442-9","article-title":"Pharmacology of lower urinary tract smooth muscles and penile erectile tissues","volume":"45","author":"Anderson","year":"1993","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.110.172288_bib4","first-page":"1","article-title":"The overactive bladder","volume":"11","author":"Bulmer","year":"2000","journal-title":"Rev Contemp Pharmacother"},{"key":"10.1124\/jpet.110.172288_bib5","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/0163-7258(93)90027-B","article-title":"Muscarinic receptors\u2014characterization, coupling and function","volume":"58","author":"Caulfield","year":"1993","journal-title":"Pharmacol Ther"},{"key":"10.1124\/jpet.110.172288_bib6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0208-0","article-title":"Signal transduction underlying the control of urinary bladder smooth muscle tone by muscarinic receptors and beta-adrenoceptors","volume":"377","author":"Frazier","year":"2008","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib7","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/0024-3205(88)90398-0","article-title":"Characterization of muscarinic receptor subtypes in human tissues","volume":"43","author":"Giraldo","year":"1988","journal-title":"Life Sci"},{"key":"10.1124\/jpet.110.172288_bib8","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1442-2042.2008.02152.x","article-title":"Long-term safety, tolerability, and efficacy of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.110.172288_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.1442-2042.2009.02286.x","article-title":"A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"16","author":"Homma","year":"2009","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.110.172288_bib10","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1442-2042.2008.02104.x","article-title":"A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladder","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1124\/jpet.110.172288_bib11","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1111\/j.1476-5381.2009.00113.x","article-title":"Quantitative analysis of the loss of muscarinic receptors in various peripheral tissues in M1-M5 single knockout mice","volume":"156","author":"Ito","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1532-5415.1998.tb01006.x","article-title":"Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride","volume":"46","author":"Katz","year":"1998","journal-title":"J Am Geriatr Soc"},{"key":"10.1124\/jpet.110.172288_bib13","first-page":"92","article-title":"Effects of imidafenacin (KRP-197\/ONO-8025), a new anti-cholinergic agent, on muscarinic acetylcholine receptors. High affinities for M3 and M1 receptor subtypes and selectivity for urinary bladder over salivary gland","volume":"57","author":"Kobayashi","year":"2007","journal-title":"Arzneimittel-Forschung"},{"key":"10.1124\/jpet.110.172288_bib14","first-page":"147","article-title":"Pharmacological effects of imidafenacin (KRP-197\/ONO-8025), a new bladder selective anti-cholinergic agent, in rats. Comparison of effects on urinary bladder capacity and contraction, salivary secretion and performance in the Morris water maze task","volume":"57","author":"Kobayashi","year":"2007","journal-title":"Arzneimittel-Forschung"},{"key":"10.1124\/jpet.110.172288_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0021-9258(19)52451-6","article-title":"Protein measurement with the Folin phenol reagent","volume":"93","author":"Lowry","year":"1951","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.110.172288_bib16","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1124\/jpet.108.136390","article-title":"In vivo quantitative autoradiographic analysis of brain muscarinic receptor occupancy by antimuscarinic agents for overactive bladder treatment","volume":"325","author":"Maruyama","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.172288_bib17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1002\/bmc.837","article-title":"Development and validation of bioanalytical methods for imidafenacin (KRP-197\/ONO-8025) and its metabolites in human urine by using liquid chromatography-tandem mass spectrometry","volume":"21","author":"Masuda","year":"2007","journal-title":"Biomed Chromatogr"},{"key":"10.1124\/jpet.110.172288_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1159\/000072681","article-title":"Pharmacological effects of KRP-197 on the human isolated urinary bladder","volume":"71","author":"Murakami","year":"2003","journal-title":"Urol Int"},{"key":"10.1124\/jpet.110.172288_bib19","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1365-2125.2007.02999.x","article-title":"Absolute bioavailability of imidafenacin after oral administration to healthy subjects","volume":"65","author":"Ohno","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1097\/01.ju.0000138472.16876.8d","article-title":"Demonstration of bladder selective muscarinic receptor binding by intravesical oxybutynin to treat overactive bladder","volume":"172","author":"Oki","year":"2004","journal-title":"J Urol"},{"key":"10.1124\/jpet.110.172288_bib21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/sj.bjp.0706184","article-title":"Muscarinic receptor binding, plasma concentration and inhibition of salivation after oral administration of a novel antimuscarinic agent, solifenacin succinate in mice","volume":"145","author":"Oki","year":"2005","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib22","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1124\/jpet.105.094508","article-title":"Advantages for transdermal over oral oxybutynin to treat overactive bladder: muscarinic receptor binding, plasma drug concentration, and salivary secretion","volume":"316","author":"Oki","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.172288_bib23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMra032662","article-title":"Management of overactive bladder","volume":"350","author":"Ouslander","year":"2004","journal-title":"New Eng J Med"},{"key":"10.1124\/jpet.110.172288_bib24","first-page":"314","article-title":"Age and sex as factors modifying the function of the blood-cerebrospinal fluid barrier","volume":"6","author":"Pakulski","year":"2000","journal-title":"Med Sci Monit"},{"key":"10.1124\/jpet.110.172288_bib25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1474-8673.2006.00377.x","article-title":"Regulation of bladder muscarinic receptor subtypes by experimental pathologies","volume":"26","author":"Ruggieri","year":"2006","journal-title":"Auton Autacoid Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib26","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/sj.bjp.0705371","article-title":"In vitro and ex vivo effects of a selective nociceptin\/orphan FQ (N\/OFQ) peptide receptor antagonist, CompB, on specific binding of [3H]N\/OFQ and [35S]GTP\u03b3S in rat brain and spinal cord","volume":"139","author":"Yamada","year":"2003","journal-title":"Br J Pharmacol"},{"key":"10.1124\/jpet.110.172288_bib27","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S0022-3565(25)32274-3","article-title":"Characterization of alpha-1 adrenergic receptors in the heart using [3H]WB4101: effect of 6-hydroxydomine treatment","volume":"215","author":"Yamada","year":"1980","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.110.172288_bib28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1254\/jphs.09R14FM","article-title":"The forefront for novel therapeutic agents based on the pathophysiology of lower urinary tract dysfunction: bladder selectivity based on in vivo drug-receptor binding characteristics of antimuscarinic agents for treatment of overactive bladder","volume":"112","author":"Yoshida","year":"2010","journal-title":"J Pharmacol Sci"},{"key":"10.1124\/jpet.110.172288_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.lfs.2010.06.008","article-title":"Noninvasive evaluation of brain muscarinic receptor occupancy of oxybutynin, darifenacin and imidafenacin in rats by positron emission tomography","volume":"87","author":"Yoshida","year":"2010","journal-title":"Life Sci"},{"key":"10.1124\/jpet.110.172288_bib30","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)09628-4","article-title":"Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins","volume":"273","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524462137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524462137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.110.172288","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:24:32Z","timestamp":1740018272000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524462137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["S0022356524462137"],"URL":"https:\/\/doi.org\/10.1124\/jpet.110.172288","relation":{},"ISSN":["0022-3565"],"issn-type":[{"type":"print","value":"0022-3565"}],"subject":[],"published":{"date-parts":[[2011,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Selective Binding of Bladder Muscarinic Receptors in Relation to the Pharmacokinetics of a Novel Antimuscarinic Agent, Imidafenacin, to Treat Overactive Bladder","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.110.172288","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}